161 related articles for article (PubMed ID: 36179410)
1. Whole-body computed tomography as first-line imaging procedure to exclude cancer in patients with neurological suspicion of paraneoplastic syndromes: shall clinical practice adhere to recommendations?
Parillo M; Quattrocchi CC; Pilato F; Di Lazzaro V; Beomonte Zobel B
Radiography (Lond); 2023 Jan; 29(1):8-13. PubMed ID: 36179410
[TBL] [Abstract][Full Text] [Related]
2. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies.
Fu P; He L; Tang N; Nie Q; Li Z
J Clin Neurosci; 2021 Jul; 89():336-342. PubMed ID: 34119290
[TBL] [Abstract][Full Text] [Related]
3. Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.
Pena Pardo FJ; García Vicente AM; Amo-Salas M; López-Fidalgo JF; Garrido Robles JA; de Ayala Fernández JÁ; Del Saz Saucedo P; Muñoz Pasadas M; Soriano Castrejón A
Clin Transl Oncol; 2017 Jan; 19(1):111-118. PubMed ID: 27139696
[TBL] [Abstract][Full Text] [Related]
4. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.
Raspotnig M; Vedeler C; Storstein A
J Neurol Sci; 2015 Jan; 348(1-2):41-5. PubMed ID: 25467140
[TBL] [Abstract][Full Text] [Related]
6. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit.
Hadjivassiliou M; Alder SJ; Van Beek EJ; Hanney MB; Lorenz E; Rao DG; Sharrack B; Tindale WB
Acta Neurol Scand; 2009 Mar; 119(3):186-93. PubMed ID: 18855873
[TBL] [Abstract][Full Text] [Related]
7. Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
Sundermann B; Schröder JB; Warnecke T; Heindel W; Schäfers M; Weckesser M; Buerke B
Acad Radiol; 2017 Oct; 24(10):1195-1202. PubMed ID: 28551401
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
[TBL] [Abstract][Full Text] [Related]
9. [(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].
García Vicente AM; Vega Caicedo CH; Mondéjar Solís R; de Ayala Fernández JÁ; Garrido Robles JA; Pena Pardo FJ; Muñoz Pasadas M; Del Saz Saucedo P; Jiménez Londoño GA; León Martín A; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):236-43. PubMed ID: 25864422
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study.
Oliveira V; Videira G; Samões R; Carneiro P; Neves E; Santos E
J Neurol Sci; 2020 Nov; 418():117103. PubMed ID: 32877801
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
13. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
Matsuhisa A; Toriihara A; Kubota K; Makino T; Mizusawa H; Shibuya H
Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026
[TBL] [Abstract][Full Text] [Related]
14. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
15. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series.
Dinoto A; Cheli M; Catalan M; Olivo S; Scali I; Bertolotti C; Sartori A; Manganotti P
Neurol Sci; 2022 Mar; 43(3):2077-2079. PubMed ID: 35000013
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics of "classical" and "non-classical" paraneoplastic neurological syndrome].
Lyu XY; Wang GP; Tang QQ; Cheng ZZ; Gui W; Tian YH
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(9):615-619. PubMed ID: 33685041
[No Abstract] [Full Text] [Related]
18. Neurological paraneoplastic syndromes in lung cancer patients.
Stefens-Stawna P; Piorunek T; Gabryel-Batura H; Kozubski W; Michalak S
Adv Exp Med Biol; 2013; 756():333-9. PubMed ID: 22836651
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.
Kristensen SB; Hess S; Petersen H; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2056-63. PubMed ID: 26194717
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of paraneoplastic neurological syndrome related to different pathological lung cancers.
Ma J; Wang A; Jiang W; Ma L; Lin Y
Thorac Cancer; 2021 Aug; 12(16):2265-2270. PubMed ID: 34242487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
